JUN 2 1 2006

PTO/SB/08B (07-05)
Approved for use through 6/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Reduction Act At A TRADE AR

1

695, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO 10/696,256 **Application Number**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

of

Sheet

Examiner Signature

1

October 29, 2003 Filing Date Azrolan First Named Inventor 1614 **Group Art Unit** Raymond J. Henley III **Examiner Name** AM-100302C1USA Attorney Docket Number

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
M	AAAA	Y. BOTTIGER, ET AL., Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus, Clin. Pharmacol. Ther., January 2001, 69(1):32-40 (abstract).	
	AAAB	M. VALGIMIGLI, ET AL., Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction, <i>JAMA</i> , May 4, 2005, Vol. 293, No. 17, pp. 2109-2117.	
	AAAC	J. MORRISETT, ET AL., Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients, <i>Journal of Lipid Research</i> , Vol. 43, 2002, pp. 1170-1180.	
B	AAAD	Z. BERGER, ET AL., Rapamycin alleviates toxicity of different aggregrate-prone proteins, Human Molecular Genetics, 2006, Vol. 15, No. 3, pp. 433-442	
			-

Considered * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Date

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.